Journal articles
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Maeva Dufies
1
Marie Nollet
2
Damien Ambrosetti
3
Wael Traboulsi
2
Julien Viotti
4
Delphine Borchiellini
5
Renaud Grépin
1
Julien Parola
6
Sandy Giuliano
1
Dominique Helley-Russick
7
Karim Bensalah
8
Alain Ravaud
9
Jean-Christophe Bernhard
10, 11
Renaud Schiappa
5
Nathalie Bardin
2
Francoise Dignat-George
2
Nathalie Rioux-Leclercq
12, 13
Stéphane Oudard
7
Sylvie Négrier
14
Jean-Marc Ferrero
5
Emmanuel Chamorey
5
Marcel Blot-Chabaud
2
Gilles Pagès
5, 6, *
*
Corresponding author
Sandy Giuliano 1
Author
Dominique Helley-Russick 7
Author
Karim Bensalah 8
Author
Alain Ravaud 9
Author
Jean-Christophe Bernhard 10, 11
Author
Renaud Schiappa 5
Author
Nathalie Bardin 2
Author
Francoise Dignat-George 2
Author IdHAL : francoise-dignat-george ORCID : https://orcid.org/0000-0001-7006-4462
Nathalie Rioux-Leclercq 12, 13
Author
Stéphane Oudard 7
Author
Sylvie Négrier 14
Author
Jean-Marc Ferrero 5
Author
Emmanuel Chamorey 5
Author
Marcel Blot-Chabaud 2
Author
Gilles Pagès 5, 6
Correspondent author IdHAL : gilles-pages
1
CSM - Centre Scientifique de Monaco (Avenue Saint-Martin, MC 98000, Monaco - Monaco)
2
C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (Faculté de Pharmacie - Timone 27, boulevard Jean Moulin 13385 Marseille cedex 5 - France)
- INRA - Institut National de la Recherche Agronomique : UMR1260 (France)
- AMU - Aix Marseille Université : UMR_S1263 (Aix-Marseille Université Jardins du Pharo 58 Boulevard Charles Livon 13284 Marseille cedex 7 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR_S1263 (101, rue de Tolbiac, 75013 Paris - France)
3
COMUE UCA - COMUE Université Côte d'Azur (2015-2019) (Parc Valrose, 28, avenue Valrose 06108 Nice Cedex 2 - France)
4
CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), Centre Antoine Lacassagne (France)
- UCA - Université Côte d'Azur (France)
5
UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (33, avenue de Valombrose, 06189 Nice - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
- UCA - Université Côte d'Azur (Parc Valrose, 28, avenue Valrose 06108 Nice Cedex 2 - France)
6
IRCAN - Institut de Recherche sur le Cancer et le Vieillissement (Faculté de médecine, 28 avenue de Valombrose 06107 Nice Cedex 2 - France)
- UNS - Université Nice Sophia Antipolis (... - 2019) (Parc Valrose - BP 2135 - 06103 Nice cedex 2 - France)
- COMUE UCA - COMUE Université Côte d'Azur (2015-2019) (Parc Valrose, 28, avenue Valrose 06108 Nice Cedex 2 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1081 (101, rue de Tolbiac, 75013 Paris - France)
- CNRS - Centre National de la Recherche Scientifique : UMR7284 (France)
- UCA - Université Côte d'Azur (Parc Valrose, 28, avenue Valrose 06108 Nice Cedex 2 - France)
7
Assistance Publique-Hôpitaux de Paris, Hopital Europeen Georges Pompidou, F-75015 Paris, France (France)
8
CHU Pontchaillou [Rennes] (2 Rue Henri le Guilloux, 35000 Rennes - France)
9
Cancérologie/Oncologie/Digestive - Département d'Oncologie [CHU Bordeaux] (GH Sud Haut-Lévêque Centre médico chirurgical Magellan - Hôpital Saint-André. - France)
- Centre médico chirurgical Magellan - GH Sud Haut-Lévêque [CHU Hôpitaux de Bordeaux] (av Magellan, 33604 Pessac Cedex. - France)
- Hôpital Saint-André [CHU de Bordeaux] (av Magellan, 33604 Pessac Cedex. - France)
10
service d'urologie [CHU Bordeaux] (Bordeaux - France)
- CHU Bordeaux [Bordeaux] (place Amélie Raba Léon 33076 BORDEAUX CEDEX - France)
11
UB - Université de Bordeaux (35, place Pey Berland - 33076 Bordeaux - France)
12
Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes] (CHU Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes - France)
- CHU Pontchaillou [Rennes] (2 Rue Henri le Guilloux, 35000 Rennes - France)
13
Irset - Institut de recherche en santé, environnement et travail (263 avenue Général Leclerc 35042 Rennes Cedex - France)
- Biosit : Biologie - Santé - Innovation Technologique - Structure Fédérative de Recherche en Biologie et Santé de Rennes (Université Rennes 1 - Campus Santé Villejean - 2, avenue Professeur Léon Bernard 35043 Rennes cedex - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1085 (101, rue de Tolbiac, 75013 Paris - France)
- EHESP - École des Hautes Études en Santé Publique [EHESP] (15, avenue du Pr. Léon Bernard - 35043 Rennes Cedex - France)
- UR1 - Université de Rennes 1 (2 rue du Thabor - CS 46510 - 35065 Rennes cedex - France)
- UNIV-RENNES - Université de Rennes (France)
- UA - Université d'Angers (Université d'Angers - 40 Rue de Rennes, BP 73532 - 49035 Angers CEDEX 01 - France)
14
Centre Léon Bérard [Lyon] (28, rue Laennec 69373 LYON Cedex 08 - France)
Abstract : The objective of the study was to use CD146 mRNA to predict the evolution of patients with non-metastatic clear cell renal cell carcinoma (M0 ccRCC) towards metastatic disease, and to use soluble CD146 (sCD146) to anticipate relapses on reference treatments by sunitinib or bevacizumab in patients with metastatic ccRCC (M1). Methods: A retrospective cohort of M0 patients was used to determine the prognostic role of intra-tumor CD146 mRNA. Prospective multi-center trials were used to define plasmatic sCD146 as a predictive marker of sunitinib or bevacizumab efficacy for M1 patients. Results: High tumor levels of CD146 mRNA were linked to shorter disease-free survival (DFS) and overall survival (OS). ccRCC patients from prospective cohorts with plasmatic sCD146 variation <120% following the first cycle of sunitinib treatment had a longer progression-free survival (PFS) and OS. The plasmatic sCD146 variation did not correlate with PFS or OS for the bevacizumab-based treatment. In vitro, resistant cells to sunitinib expressed high levels of CD146 mRNA and protein in comparison to sensitive cells. Moreover, recombinant CD146 protected cells from the sunitinib-dependent decrease of cell viability. Conclusion: CD146/sCD146 produced by tumor cells is a relevant biological marker of ccRCC aggressiveness and relapse on sunitinib treatment.
Document type :
Journal articles
Domain :
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-02060593
Contributor : Françoise Dignat-George Connect in order to contact the contributor
Submitted on : Friday, October 25, 2019 - 12:10:49 PM
Last modification on : Sunday, May 1, 2022 - 3:16:17 AM
Long-term archiving on: : Sunday, January 26, 2020 - 3:22:38 PM
Contributor : Françoise Dignat-George Connect in order to contact the contributor
Submitted on : Friday, October 25, 2019 - 12:10:49 PM
Last modification on : Sunday, May 1, 2022 - 3:16:17 AM
Long-term archiving on: : Sunday, January 26, 2020 - 3:22:38 PM
File
v08p2447.pdf
Publication funded by an institution
Licence
Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Identifiers
- HAL Id : hal-02060593, version 1
- DOI : 10.7150/thno.23002
- PUBMED : 29721091
- PRODINRA : 427682
- WOS : 000429880400002
Collections
UNIV-AMU | UNIV-RENNES | UNIV-COTEDAZUR | UNIV-RENNES1 | INRA | CNRS | IRSET | IRSET-8 | UR1-UFR-SVE | UNIV-ANGERS | INRAE | UR1-BIO-SA
Citation
Maeva Dufies, Marie Nollet, Damien Ambrosetti, Wael Traboulsi, Julien Viotti, et al.. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. Theranostics, Ivyspring International Publisher, 2018, 8 (9), pp.2447-2458. ⟨10.7150/thno.23002⟩. ⟨hal-02060593⟩
Metrics
Record views
103
Files downloads